Pharmaceutical - USA

Filter

Current filters:

USA

Popular Filters

1 to 25 of 685 results

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

27-11-2014

US pharma major Bristol-Myers Squibb has received a Complete Response Letter from the US Food and Drug…

Anti-viralsBristol-Myers SquibbdaclatasvirPharmaceuticalRegulationUSA

OPEN Act introduced in USA to repurpose drugs for rare diseases

OPEN Act introduced in USA to repurpose drugs for rare diseases

26-11-2014

Last week, US Representatives Gus Bilirakis (Republican, Florida) and G K Butterfield (Democrat, North…

PharmaceuticalPoliticsRare diseasesRegulationUSA

Apellis Pharma to acquire former parent Potentia

Apellis Pharma to acquire former parent Potentia

26-11-2014

USA-based Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals,…

Apellis PharmaceuticalsMergers & AcquisitionsOphthalmicsPharmaceuticalPotentia PharmaceuticalsUSA

FDA adds warning to Tecfidera label after patient death

FDA adds warning to Tecfidera label after patient death

26-11-2014

The US Food and Drug Administration has issued a warning that a patient with multiple sclerosis who was…

Biogen IdecCNS DiseasesPharmaceuticalRegulationTecfideraUSA

Janssen submits NDA for Yondelis in soft tissue sarcoma

Janssen submits NDA for Yondelis in soft tissue sarcoma

25-11-2014

US health care giant Johnson & Johnson’s subsidiary Janssen Research & Development has submitted a…

Janssen Research and DevelopmentOncologyPharmaceuticalRegulationUSAYondelis

US FDA pushes back decision date for Novartis’ panobinostat

US FDA pushes back decision date for Novartis’ panobinostat

25-11-2014

The US Food and Drug Administration has extended its priority review period by up to three months for…

FarydakNovartisOncologypanobinostatPharmaceuticalRegulationUSA

Trimel and Endo agree on Natesto manufacturing and marketing collaboration

Trimel and Endo agree on Natesto manufacturing and marketing collaboration

24-11-2014

Trimel Biopharma, a subsidiary of Canada's Trimel Pharmaceuticals Corp, has signed an agreement with…

CanadaEndoLicensingMarkets & MarketingMen's HealthPharmaceuticalTrimel PharmaceuticalsUSA

AARP prescription drug Price Watch report shows cost of medicines vastly outpacing rate of inflation

AARP prescription drug Price Watch report shows cost of medicines vastly outpacing rate of inflation

24-11-2014

The latest Rx Price Watch Report from the American Association of Retired Persons (AARP) has found that…

Business FinanceHealthPharmaceuticalPharmaceutical sciencesPharmacologyPricingUSA

Takeda US president quits

21-11-2014

The president of Japanese drug major Takeda Pharmaceutical’s (TYO: 4502) US subsidiary, Douglas Cole,…

BoardroomManagementPharmaceuticalTakeda PharmaceuticalUSA

FDA approves Purdue’s opioid analgesic Hysingla ER

21-11-2014

The US Food and Drug Administration has approved Hysingla ER (hydrocodone bitartrate), an extended-release…

Hysingla ERNeurologicalPharmaceuticalPurdue PharmaUSAZogenixZohydro

HHS and NIH take steps to enhance clinical trial results transparency

20-11-2014

The US Department of Health and Human Services today issued a Notice of Proposed Rulemaking (NPRM), which…

PharmaceuticalRegulationResearchUSA

Shire to relocate 500 employees in formation of new hub in Lexington, Massachusetts

Shire to relocate 500 employees in formation of new hub in Lexington, Massachusetts

19-11-2014

Following AbbVie’s recent abandonment of a $53 billion takeover offer, Ireland-headquartered drugmaker…

Business FinancePharmaceuticalPunctuationShireUSA

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

18-11-2014

Pharma giant Merck & Co has announced that the study investigating LDL-cholesterol-lowering drug Vytorin…

Cardio-vascularMerck & CoPharmaceuticalResearchUSAVytorinZetia

Extended benefit of dual antiplatelet therapy after one year is proven in study

Extended benefit of dual antiplatelet therapy after one year is proven in study

18-11-2014

New research published in the New England Journal of Medicine shows that while dual antiplatelet therapy…

Cardio-vascularClopidogrelPharmaceuticalprasugrelResearchUSA

Allergan agrees to $66 billion acquisition by Actavis

Allergan agrees to $66 billion acquisition by Actavis

17-11-2014

Confirming what were becoming ever stronger rumors over the weekend, Ireland-headquartered Actavis this…

ActavisAllerganMergers & AcquisitionsPharmaceuticalUSAValeant Pharmaceuticals International

Clear survival benefit for B-MS’ Opdivo in advanced melanoma patients

Clear survival benefit for B-MS’ Opdivo in advanced melanoma patients

17-11-2014

US drug major Bristol-Myers Squibb has announced results from a study comparing Opdivo (nivolumab) to…

Bristol-Myers SquibbOncologyOpdivoPharmaceuticalResearchUSA

Study shows mutations in NPC1L1 protein cut coronary heart disease

Study shows mutations in NPC1L1 protein cut coronary heart disease

14-11-2014

A new study part-funded by US pharma giant Merck & Co (NYSE: MRK) has found that mutations in a gene…

Cardio-vascularCoronary heart diseaseMerck & CoPharmaceuticalResearchUnited StatesUSAZetia

FDA approves sNDA for Janssen's Invega Sustenna in schizoaffective disorder

FDA approves sNDA for Janssen's Invega Sustenna in schizoaffective disorder

13-11-2014

The US Food and Drug Administration has approved the supplemental New Drug Applications (sNDAs) from…

Invega SustennaJanssenNeurologicalPharmaceuticalRegulationUSA

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

13-11-2014

Generic and branded specialty pharma company Par Pharmaceuticals has received approval for its New Drug…

HematologyPar PharmaceuticalsPharmaceuticalRegulationUSAVasostrict

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

12-11-2014

Pharma giant Merck & Co has presented results from its Phase II trial of grazoprevir/elbasvir, with or…

grazoprevir/elbasvirMerck & CoNephrology and HepatologyPharmaceuticalResearchUSA

Polyphor’s POL7080 receives QIDP designation from the FDA

12-11-2014

Privately-held Swiss pharma firm Polyphor says that the US Food and Drug Administration has designated…

Antibiotics and Infectious diseasesPharmaceuticalPOL7080PolyphorRegulationRocheUSA

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

Afaxys announces wider US availability of ella emergency contraceptive

12-11-2014

US drugmaker Afaxys Pharmaceuticals, a division of Afaxys Inc, has announced wider US availability of…

AfaxysellaHRA PharmaMarkets & MarketingPharmaceuticalReproductiveUSAWomen's Health

Durect to ‘refine the path’ of Posidur program

Durect to ‘refine the path’ of Posidur program

12-11-2014

US drugmaker Durect Corporation says that it has received meeting minutes from its face-to-face meeting…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

1 to 25 of 685 results

Parexel

Parexel

Back to top